Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
Oaknin, Ana, Moore, Kathleen, Meyer, Tim, López-Picazo González, José, Devriese, Lot A, Amin, Asim, Lao, Christopher D, Boni, Valentina, Sharfman, William H, Park, Jong Chul, Tahara, Makoto, Topalian, Suzanne L, Magallanes, Manuel, Molina Alavez, Alejandro, Khan, Tariq Aziz, Copigneaux, Catherine, Lee, Michelle, Garnett-Benson, Charlie, Wang, Xuya, Naumann, R Wendel
Published in The lancet oncology (01.05.2024)
Published in The lancet oncology (01.05.2024)
Get full text
Journal Article
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma
Fuchs, Charles S., Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H., Tabernero, Josep, Chau, Ian, Ducreux, Michel, Mendez, Guillermo Ariel, Molina Alavez, Alejandro, Takahari, Daisuke, Mansoor, Wasat, Lacy, Jill, Gorbunova, Vera, Ferry, David, Lin, Ji, Das, Mayukh, Shah, Manish A.
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article